Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Conditions:   Metastatic Lung Small Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Neuroendocrine Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Stage III Lung Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Unresectable Lung Small Cell Carcinoma;   Unresectable  Malignant Solid Neoplasm;   Unresectable Neuroendocrine Carcinoma;   Unresectable Pancreatic Adenocarcinoma Interventions:   Drug: ATR Kinase Inhibitor BAY1895344;   Drug: Liposomal Irinotecan;   Drug: Topotecan Hydrochloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials